Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216027 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
A Phase 2 study of Atopic Dermatitis and Eczema, Atopic, sponsored by Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 10
- Study locations
NCT07216027: Active Phase 2 study of Atopic Dermatitis and Eczema, Atopic, sponsored by Pfizer.
NCT07216027 is a Phase 2 study of Atopic Dermatitis and Eczema, Atopic that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 200 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216027, a Phase 2 study of Atopic Dermatitis and Eczema, Atopic, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 years of age or more; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. Eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12, and have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. Participants will have blood and urine tests and must answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to participants receiving placebo. This will help to understand if PF-08049820 is safe and effective.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-08049820
Study Locations (10)
Florida
- Gsi Clinical Research - Margate
- Skin Research of South Florida - Miami
Kanagawa
- Kosugi Dermatology Clinic - Kawasaki-shi
- Queen's Square Medical Facilities - Yokohama
Tokyo
- Nihonbashi Sakura Clinic - Chuo-ku
- Fukuwa Clinic - Chuo-ku
California
- Clinical Science Institute - Santa Monica
Tennessee
- Goodlettsville Dermatology Research - Goodlettsville
Gunma
- Hattori Dermatology Clinic - Takasaki
Osaka
- Dermatology and Ophthalmology Kume Clinic - Sakai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2027-08-23 |
| Phase | Phase 2 |
What the registry record for NCT07216027 still lists
NCT07216027 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07216027 lists 10 locations in 7 states (Florida, Kanagawa, Tokyo).
Frequently Asked Questions
What is clinical trial NCT07216027 about?
NCT07216027 is a clinical study titled "A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema". The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. ...
What is the current status of trial NCT07216027?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-20. Estimated completion is 2027-08-23.
What conditions does trial NCT07216027 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema, Atopic.
What interventions are being tested in trial NCT07216027?
The interventions under investigation include: Placebo (DRUG), PF-08049820 (DRUG).
Who is sponsoring clinical trial NCT07216027?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216027 being conducted?
This trial has 10 study locations across California, Florida, Tennessee, Gunma, Kanagawa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07216027's enrollment target sits among peer trials
200 56th of 150 higher than 89 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
- NCT00568490 · 200 participants
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI